ProMIS Neurosciences, Inc. Quarterly report [Sections 13 or 15(d)]

NET LOSS PER SHARE - Outstanding potentially dilutive common shares (Details) - shares	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	9,421,952	2,341,852
Options issued and outstanding under stock option plan
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	181,779	142,634
Warrants
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	9,240,131	2,199,175
Deferred share units
NET LOSS PER SHARE
Dilutive common shares equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive	42	42